Utilization Trends of SGLT2 Inhibitors in Croatian Clinical Practice: Observational Analysis
Medicina · 31.01.2026 · 62 (2) · 286
DOI: 10.3390/medicina62020286 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Medicina, online erschienen am 31.01.2026. Verfasst von Andrej Belančić und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as key agents in the management of type 2 diabetes mellitus (T2DM), with expanding indications in heart failure and chronic kidney disease. This study assessed national trends in SGLT2 inhibitor utilization in Croatia between 2014 and 2024 using data from IQVIA. Materials and Methods: Drug use was quantified in defined daily doses per 1000 inhabitants per day (DDD/1000/day), alongside financial expenditure and prescribing patterns.
Results
Since their market introduction in 2014, SGLT2 inhibitor utilization increased from 0.49 to 11.63 DDD/1000/day by 2024. Fixed-dose combinations with metformin accounted for a growing share of prescribing, reflecting a shift toward adherence-friendly regimens. Dapagliflozin was the most prescribed agent, likely due to broad therapeutic versatility and favorable pricing. Despite these trends, SGLT2 inhibitors (monotherapy) seem to be underutilized, accounting for just 12% of non-insulin antidiabetic prescriptions in 2024.
Conclusions
These findings highlight the gradual integration of SGLT2 inhibitors into national clinical practice and emphasize the need for targeted educational and policy efforts to overcome therapeutic inertia and align prescribing with evidence-based cardio-renal-metabolic care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
- Faculty of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia.
- Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, 10000 Zagreb, Croatia.
- Department of Internal Medicine, Division of Metabolic Diseases, University Hospital Center Zagreb, 10000 Zagreb, Croatia.
- School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
ORCID-Profile: Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Ivan Pećin, Bojan Jelaković, Dinko Vitezić
Zitieren
APA
Belančić, A., Kučan Štiglić, M., Jelaković, A., Pećin, I., Jelaković, B., & Vitezić, D. (2026). Utilization Trends of SGLT2 Inhibitors in Croatian Clinical Practice: Observational Analysis. Medicina, 62(2), 286. https://doi.org/10.3390/medicina62020286
Vancouver
Belančić A, Kučan Štiglić M, Jelaković A, Pećin I, Jelaković B, Vitezić D. Utilization Trends of SGLT2 Inhibitors in Croatian Clinical Practice: Observational Analysis. Medicina. 2026;62(2):286. doi:10.3390/medicina62020286
BibTeX
@article{Belani2026,
author = {Belančić, Andrej and Kučan Štiglić, Marta and Jelaković, Ana and Pećin, Ivan and Jelaković, Bojan and Vitezić, Dinko},
title = {Utilization Trends of SGLT2 Inhibitors in Croatian Clinical Practice: Observational Analysis},
journal = {Medicina},
year = {2026},
volume = {62},
number = {2},
pages = {286},
doi = {10.3390/medicina62020286}
}
EUVIMED